Sign In
Buy NUVA
$39.75
+0 (+0%)
At Close: Nov 30, 2023
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
12:02pm, Tuesday, 03'rd May 2022
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results
04:10pm, Wednesday, 20'th Apr 2022
SAN DIEGO , April 20, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integ
Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus
01:13pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.
Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus
10:32am, Thursday, 31'st Mar 2022
Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
12:55pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
10:32am, Tuesday, 29'th Mar 2022
Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022
02:05pm, Monday, 28'th Mar 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Bank of New York Mellon Corp (NYSE:BK) was changed from Underweight to Equal-Weight. In the fourth quarter, Bank of New York Mellon showed an
Why Is NuVasive (NUVA) Down 2.2% Since Last Earnings Report?
03:30pm, Friday, 25'th Mar 2022 Zacks Investment Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is NuVasive (NUVA) Down 2.2% Since Last Earnings Report?
01:33pm, Friday, 25'th Mar 2022
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?
NuVasive''s Turnaround Story Needs A Boost From Better Results
07:19pm, Tuesday, 01'st Mar 2022 Seeking AlphaNuVasive's Turnaround Story Needs A Boost From Better Results
02:19pm, Tuesday, 01'st Mar 2022
NuVasive managed a modest beat in Q4'21 and the initial guide for 2022 was okay, but the company needs to start showing clear evidence of market share regrowth.
NuVasive Inc. (NUVA) Stock Behavior Is Not Predictable
04:00pm, Saturday, 26'th Feb 2022 Stocks Register
NuVasive Inc. (NASDAQ:NUVA) concluded the trading at $54.04 on Friday, February 25 with a rise of 1.89% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $53.04 and 5Y monthly beta was reading 1.20 with its price kept floating in the range … NuVasive Inc. (NUVA) Stock Behavior Is Not Predictable Read More »
NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up
03:05pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up
11:35am, Thursday, 24'th Feb 2022
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
